Press Releases October 2, 2026 04:05 PM

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aardvark Therapeutics Issues Employee Stock Option Grant as Inducement Under Nasdaq Rule

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
AARD

Aardvark Therapeutics, a clinical-stage biopharmaceutical company, announced an inducement grant of stock options to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant consists of options for 60,000 shares of common stock at an exercise price of $5.27 per share, vesting over four years. This is part of the company's equity incentive plan and aims to attract talent for its metabolic disease drug development programs.

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AARD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aardvark Therapeutics granted 60,000 stock options to a new employee as an inducement grant under Nasdaq rules.
  • The exercise price is $5.27 per share, matching the closing price on the grant date, with vesting over four years.
  • The company is focused on developing small-molecule therapeutics targeting hunger signaling pathways for metabolic diseases, including Prader-Willi Syndrome.

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on October 1, 2026, one new employee was granted an inducement award consisting of a stock option to purchase 60,000 shares of common stock.  

The option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan and was granted as an inducement material to the employee’s employment with Aardvark in accordance with Nasdaq Listing Rule 5635(c)(4). 

The exercise price of the option is equal to the closing price of Aardvark’s common stock on the date of grant, or $5.27. The option will vest over four years, with 25% of the total number of shares vesting on the one-year anniversary of the date of commencement of such employee’s employment with Aardvark and 1/48th of the total number of shares subject to the option vesting monthly thereafter, subject to continued employment. 

About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. For more information, visit www.aardvarktherapeutics.com. 

Investor and Media Contact:
Courtney Mogerley
Argot Partners
(212) 600-1902
[email protected]


Risks

  • The long vesting period means retention and future performance of the new employee impact the company's operations and possibly the stock's value.
  • Development of novel therapies for metabolic diseases carries typical biopharma clinical and regulatory risks.
  • Market reception to inducement grants is generally neutral, and without immediate operational milestones, stock impact is limited.

More from Press Releases

Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026